Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms
A legfontosabb adatok
- Ki végzi
- Gerd Care Medical Ltd
- Hol
- Chicago (Egyesült Államok)A helyszín megnézéseMég 1 másik országban, 4 helyszínen
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 84 fő, tervezett
- Kezdés
- 2024. szept. 15.
- Várható befejezés
- 2027. ápr.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- eGERD device
- eGERD_Sham
- A regiszteradat frissítve
- 2026. június 23.
Ki vehet részt
- Életkor
- 22 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 33 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female, aged 22 - 75
- Has been typically suffering from at least three heartburn and/or regurgitation episodes per week during the past three months
- Undergone a wireless (Bravo) pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2) in at least 2 monitoring days AND when averaged over all monitoring days of the test; or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD; or Undergone a catheter-based pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2); or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD
- Able and willing to give informed consent for participation in the study and to comply with all study requirements, including operating the smartphone application
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study
Ki nem vehet részt
- Previously undergoing gastric or esophageal surgery
- Active peptic ulcer disease or symptomatic helicobacter
- History of suspected or confirmed esophageal or gastric cancer
- History of any other malignancy in the last 2 years
- Severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker / defibrillator
- Known allergy to the device's adhesives/patches
- Severe pulmonary diseases
- History of significant multisystem diseases (e.g. kidney failure, liver failure)
- Known autoimmune or a connective tissue disorder (e.g. scleroderma, CREST-syndrome, Sjogren's Syndrome), requiring therapy in the preceding 2 years
- History of Barrett's esophagus
- Known history of sliding hiatal hernia ≥4 cm in the last 3 years
- Known history of erosive esophagitis Grade C or D (LA classification) in the past 5 years
- History of gastroparesis
- History of fibromyalgia, epilepsy, endometriosis
- Other medical conditions/medications that would interfere with subject safety or data collection in the opinion of the PI
- Uncontrolled diabetes mellitus, defined as HbA1c \> 7.5%
- Esophageal or gastric varices or esophageal peptic stricture
- Severe dysphagia
- Pregnant women or women intending to become pregnant during the trial period
- Having any implanted electrical device (e.g. sacral nerve stimulation, brain stimulator, others)
- Para-esophageal hiatal hernia
- Obesity, defined as BMI\>32
- Umbilical hernia \>3cm
- Past usage experience with the study device
- Those currently enrolled in any other interventional clinical study
- Inability to sign the informed consent
- Inability to understand and fill the reports and questionnaires included in the study
- Inability to follow the study requisites
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 22 és 75 év között vagy?
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 4 helyszínen
- Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern UniversityChicago, Egyesült ÁllamokContact: Ofer Z Fass, MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD).
A teljes eredeti leírásKevesebb
The main questions this research aims to answer are:
1. Does the eGERD device reduce acidity in the esophagus? 2. Does the eGERD device reduce GERD symptoms such as heartburn and regurgitation? 3. What medical problems do participants have when using the eGERD device?
To assess the acidity in the esophagus, a wireless standard-of-care capsule called Bravo will be placed in the participants esophagus (throat) for several days.
To assess GERD symptoms, participants will be requested to report symptoms they experience using a smartphone application.
Researchers will compare a real version of the eGERD device to a sham version (a look-alike device that has no therapeutic effect) to see if the eGERD device is effective in treating GERD.
A vizsgálat 2 csoportja
- ActiveA vizsgált kezelés
Participants in the active arm will be using a functional version of the investigational device for 28 days.
Kezelés: eGERD device
- ControlSzínlelt kezelés, összehasonlításként
Participants in the control arm will be using a sham version of the investigational device for 28 days.
Kezelés: eGERD_Sham
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- The Effect of Non-Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD)
- Illeszkedési kérdések
- Forrás: NCT06613438: ki vehet részt
- A regiszteradat frissítve
- 2026. június 23.